公开(公告)号：US20160296511A1

公开(公告)日：2016-10-13

申请号：US15186163

申请日：2016-06-17

Applicant: Massimo Filippi ,  Giancarlo Comi ,  Maria Assunta Rocca

Inventor： Massimo Filippi ,  Giancarlo Comi ,  Maria Assunta Rocca

IPC: A61K31/4704 ,  A61K9/00

CPC classification number: A61K31/4704 ,  A61K9/0053

Abstract: This invention provides methods for inhibiting or reducing thalamic damage in a subject comprising administering to the subject an amount of laquinimod, wherein the subject is a human patient afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome who has been determined to have thalamic damage at baseline, a subject afflicted with a disease or disorder other than a form of multiple sclerosis or a clinically isolated syndrome, or a subject not afflicted with a form of multiple sclerosis or a presenting clinically isolated syndrome, and laquinimod and laquinimod pharmaceutical compositions for use thereof. This invention also provides methods for inhibiting or reducing tremor or spasticity in a subject afflicted by tremor or spasticity, comprising administering to the subject an amount of laquinimod, and laquinimod and laquinimod pharmaceutical compositions for use thereof.

Abstract translation: 本发明提供了抑制或减少受试者的丘脑损伤的方法，其包括向受试者施用一定量的拉喹莫德，其中受试者是患有多发性硬化症形式的人类患者或呈现临床分离的综合征，其被确定为具有丘脑 患有基线时的损伤，患有多发性硬化症或临床分离综合征形式的疾病或障碍的受试者或未患有多发性硬化症或呈现临床分离综合征形式的受试者，以及拉喹莫德和拉喹莫德药物组合物 使用它。 本发明还提供了抑制或减轻由震颤或痉挛状态所引起的震颤或痉挛状态的方法，其包括给予受试者一定量的用于其的拉喹莫德和拉喹莫德和拉喹莫德药物组合物。

公开(公告)号：US20140107154A1

公开(公告)日：2014-04-17

申请号：US14049411

申请日：2013-10-09

Applicant: Massimo Filippi ,  Giancarlo Comi ,  Maria Assunta Rocca

Inventor： Massimo Filippi ,  Giancarlo Comi ,  Maria Assunta Rocca

IPC: A61K31/4704

CPC classification number: A61K31/4704 ,  A61K9/0053

Abstract: This invention provides methods for inhibiting or reducing thalamic damage in a subject comprising administering to the subject an amount of laquinimod, wherein the subject is a human patient afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome who has been determined to have thalamic damage at baseline, a subject afflicted with a disease or disorder other than a form of multiple sclerosis or a clinically isolated syndrome, or a subject not afflicted with a form of multiple sclerosis or a presenting clinically isolated syndrome, and laquinimod and laquinimod pharmaceutical compositions for use thereof. This invention also provides methods for inhibiting or reducing tremor or spasticity in a subject afflicted by tremor or spasticity, comprising administering to the subject an amount of laquinimod, and laquinimod and laquinimod pharmaceutical compositions for use thereof.

Abstract translation: 本发明提供了抑制或减少受试者的丘脑损伤的方法，其包括向受试者施用一定量的拉喹莫德，其中受试者是患有多发性硬化症形式的人类患者或呈现临床分离的综合征，其被确定为具有丘脑 患有基线时的损伤，患有多发性硬化症或临床分离综合征形式的疾病或障碍的受试者或未患有多发性硬化症或呈现临床分离综合征形式的受试者，以及拉喹莫德和拉喹莫德药物组合物 使用它。 本发明还提供了抑制或减轻由震颤或痉挛状态所引起的震颤或痉挛状态的方法，其包括给予受试者一定量的用于其的拉喹莫德和拉喹莫德和拉喹莫德药物组合物。